Ignite Creation Date:
2025-12-25 @ 3:00 AM
Ignite Modification Date:
2026-01-01 @ 5:47 AM
Study NCT ID:
NCT00426933
Status:
COMPLETED
Last Update Posted:
2010-09-14
First Post:
2007-01-23
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections
Sponsor:
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-01
Start Date Type:
None
Primary Completion Date:
2007-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2007-09
Completion Date Type:
ACTUAL
First Submit Date:
2007-01-23
First Submit QC Date:
None
Study First Post Date:
2007-01-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2010-09-13
Last Update Post Date:
2010-09-14
Last Update Post Date Type:
ESTIMATED